Effect of Doorvadi Cream In Atopic Dermatitis (Paridagdha Chavi) in Childrens A single group study

Phase 4

Not yet recruiting

Conditions: Other atopic dermatitis. Ayurveda Condition: KUSHTHAM,

Registration Number: CTRI/2023/03/050626

Lead Sponsor: Mahant Digvijaynath Ayurved Chikitsalaya

Brief Summary: Atopic dermatitis (AD) is the most common chronic inflammatoryskin disorder in children the prevalence of AD has almost tripled in industrializedcountries during last three decade Approximate 15%-30% children are affected.Approximately 45% of cases of atopic dermatitis begin within 6 month of life 60%begins during first year 85% begins before 5 year of age. Up to 70% of childrenhave a reemission before adolescence.

Thenumber of AD patient is beyond the level that can be dealt with atclinics and it is time to make an effort toreduce the number of AD patients in the community

The introduction of topical steroids of varyingpotency has rendered the therapy of inflammatory coetaneous disorders moreeffective and less time-consuming. However, the usefulness of these has becomea double edged sword with constantly rising instances of abuse and misuseleading to serious local, systemic and psychological side effects.

Cornerstone of therapy of AD is tropical differentformulation because impaired skin barrier is pivotal in the pathogenesis of AD.

So it is a need of more radical approach through ayurveda to manage ADwith no side effect with help of herbal medicine in the form of cream make theherbal barrier on impaired skin

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 196

Inclusion Criteria

1-Pre diagnosed case of atopic dermatitis 2-Having mild and moderate atopic dermatitis according to TIS Scoring.

Exclusion Criteria

The exclusion criteria are as follows: (1) lesions with oozing, (2) oral administration of corticosteroids, immunosuppressantâ€™s, or antibiotics 4 weeks prior to study entry, (3) administration of topical glucocortecoids, immunosuppressantâ€™s, or antibiotics, or phototherapy, 2 weeks prior to study entry, (4) burn or trauma on the lesions, (5) active skin diseases without AD, (6) renal or liver dysfunction, (7) other uncontrolled chronic diseases, (8) participation in other clinical trials within 1 month of enrollment, (9) inability to understand the written consent or to engage in this study due to mental impairment or other emotional or mental problems, and (10) judgment by experts that the potential subjectâ€™s participation is inappropriate.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduced redness	7th day

Secondary Outcome Measures

Name	Time	Method
TIS score reduced	15th & 45th day

Trial Locations

Locations (1): Mahant Digvijaynath ayurveda chikitsalaya
🇮🇳
Gorakhpur, UTTAR PRADESH, India
Mahant Digvijaynath ayurveda chikitsalaya
🇮🇳Gorakhpur, UTTAR PRADESH, India
Dr Neeraj Kumar Gupta
Principal investigator
9650970307
neeraj.bvp.coa@gmail.com